12:00 AM
 | 
Dec 21, 2009
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Stimuvax: Phase III started

Merck began the double-blind, placebo-controlled, Asian Phase III INSPIRE trial to evaluate 1,000 µg subcutaneous Stimuvax given weekly for 8 weeks in 420 patients with unresectable, stage III NSCLC....

Read the full 122 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >